Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough SARS …
Background Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …
[HTML][HTML] Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough …
MS Durstenfeld, MJ Peluso, F Lin, ND Peyser, C Isasi… - 2023 - europepmc.org
Background Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …
[PDF][PDF] Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough …
MS Lin, TWCPD MS, TJ Henrich, MS Durstenfeld… - scholar.archive.org
Background: Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …